Healthcare Industry News: Phyton Biotech
News Release - March 27, 2007
HEALTHPOINT and Coria Align as DFB Branded PharmaceuticalsDFB Focuses R&D, Consolidates Operations at Fort Worth Headquarters
FORT WORTH, Texas, March 27 (HSMN NewsFeed) -- H. Paul Dorman, Chairman and CEO of Fort Worth-based DFB Pharmaceuticals, Inc., has reorganized the company to place all branded DFB pharmaceutical businesses under DFB Branded Pharmaceuticals, with HEALTHPOINT®, Ltd., veteran Michael E. Steadman at the helm.
DFB Branded Pharmaceuticals is one of three DFB business segments. The other two are DFB Pharmaceutical Services, represented by DPT Laboratories, Ltd. (San Antonio, Texas, and Lakewood, NJ) and DFB Biotechnology, represented by Phyton Biotech, Inc. (Princeton, NJ, and Ahrensburg, Germany).
The realignment unites HEALTHPOINT Tissue Management; Coria Laboratories, Ltd.; HEALTHPOINT International; and HEALTHPOINT Surgical as the new DFB Branded Pharmaceuticals. With the change, the two formerly autonomous Tissue Management and Surgical divisions combine under one HEALTHPOINT umbrella.
"DFB and its operating companies have achieved astonishingly rapid yet sustainable growth in an increasingly complex environment," Mr. Dorman said. "With this new structure, we streamline our business, continue momentum, and create an even stronger launch pad for future expansion."
DFB Branded Pharmaceuticals has a workforce of approximately 400, with over half of the segment's employees in field sales roles. This team will market proprietary over-the-counter, prescription, and biopharmaceutical products for skin and soft tissue indications for HEALTHPOINT and Coria. The segment will also explore potential expansion into other niche markets domestically and internationally.
According to Mr. Dorman, DFB centralized functions like regulatory, medical, and clinical affairs will be leveraged and aligned to provide specialized support to both Coria and HEALTHPOINT. Research and development will be more closely associated with, and accountable for, the commercial product portfolios of each division.
All branded pharmaceutical businesses and managerial support functions will be located at the DFB Fort Worth headquarters campus.
Mr. Steadman, most recently senior vice president of DFB and president of the HEALTHPOINT Tissue Management division, will step up to lead DFB Branded Pharmaceuticals as Group President and Chief Operating Officer. In leadership positions for the commercial divisions are Rob Bancroft, General Manager of HEALTHPOINT and Steve Clark, President of Coria. Outside the U.S., the segment's endeavors are led by Jay Nisbet, Senior Director of International.
Mr. Steadman will also work closely alongside and guide DFB Branded Pharmaceutical leaders Duncan Aust, PhD, Senior Vice President, Research and Development; Mike Bernstein, MPH, Vice President, Regulatory Affairs; Herbert Slade, MD, Chief Medical Officer; Mike Carmena, Senior Director, Finance and Administration; Gerry Keith, Deputy General Counsel; and Mary Beth Dudley, Senior Director, Human Resources.
"Entrepreneurial spirit has been at the core of the leadership and talent that has driven our success to date," Mr. Steadman noted. "This reorganization will reenergize that spirit and determination in our people and further expand and strengthen capabilities in our product portfolios."
Innovative products are at the nucleus of any successful pharmaceutical company, according to Mr. Steadman. DFB's scientific team dedicated to pharmaceutical sciences for HEALTHPOINT and Coria will provide program management, drug discovery, drug development, drug safety, clinical development, regulatory oversight, planning, and administration services. The team is housed in a new 78,000 square foot research and development facility that extends the DFB campus to nearby West Vickery Boulevard; the facility began operation November 2006. Dr. Aust oversees the new facility's operations with Mr. Bernstein and Dr. Slade.
"We will concurrently fortify our strategic commitment to current markets and increase the value of our product portfolios for patients and practitioners," said Mr. Steadman. "We've set the stage to refocus and propel growth."
DFB Branded Pharmaceuticals has a rich heritage, strong business performance, and a keen eye on the future, according to Mr. Steadman.
DFB's success is reflected in its growing facilities, expanding product portfolio, and increasing sales numbers.
"Our organizational improvements greatly strengthen our company," Mr. Dorman emphasized. "By sharply increasing strategic focus on the management of the businesses, we can assure successful navigation of the twists and turns in this progressively more complicated and demanding marketplace.
"We've got the right products and people, in the right positions, at the right time, to drive continued success."
DFB Pharmaceuticals, Inc. has 1,700 employees worldwide, with DFB Branded Pharmaceuticals staff working in the Fort Worth headquarters campus. DFB finance and information technology will move from San Antonio to Fort Worth over the next 12 to 18 months.
DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB's business structure is organized by segments: Branded Pharmaceuticals, Biotechnology, and Pharmaceutical Services. The Branded Pharmaceuticals segment includes HEALTHPOINT, Ltd., active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for tissue management and surgical indications since 1992; and Coria Laboratories, Ltd., focusing on dermatology and treatments of diseases that affect the skin, hair, and nails. Pharmaceutical Services includes DPT Laboratories, Ltd., a Contract Development and Manufacturing Organization (CDMO) and industry source for semi-solid and liquid development and manufacturing services for the world's leading pharmaceutical, biotechnology, and healthcare companies. The Biotechnology segment encompasses Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries; and Phyton's German subsidiary, Phyton GmbH, which operates the world's largest commercial cGMP manufacturing facility for plant cell fermentation. DFB's Web site: http://www.dfb.com.
Source: DFB Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.